CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis - PubMed
a day ago
- #Biomarker
- #Immunotherapy
- #Leptomeningeal Metastasis
- CSF proteomics identified ADGRG1 as a predictive biomarker for intrathecal immune checkpoint inhibitor (ICI) response in leptomeningeal metastasis (LM).
- The study involved 62 LM patients treated with intrathecal pemetrexed (InPe) with or without ICIs, analyzing CSF and serum proteomics using the Olink platform.
- A five-protein CSF signature (ADGRG1, CD28, CCL23, DCN, IL-15) showed high predictive accuracy (AUC up to 1 in validation cohorts).
- ADGRG1 was significantly higher in non-responders at baseline and decreased post-treatment, suggesting a role in LM progression and macrophage biology.
- The study provides the first high-content proteomic atlas of intrathecal ICI therapy in LM, highlighting immune remodeling and a CSF-based predictive model.